Showing results (111-120 of 156) with videos related to

Sort By:
Pageof 16
Cancers|March 11, 2023
Urokinase-Type Plasminogen Activator Receptor (uPAR) Cooperates with Mutated <i>KRAS</i> in Regulating Cellular Plasticity and Gemcitabine Response in Pancreatic AdenocarcinomasLuogen Peng, Yuchan Li, Sha Yao, et al.
Ebiomedicine|October 11, 2019
SPARC dependent collagen deposition and gemcitabine delivery in a genetically engineered mouse model of pancreas cancerIswarya Ramu, Sören M Buchholz, Melanie S Patzak, et al.
Journal of Hematology & Oncology|July 10, 2019
Nuclear factor of activated T-cells, NFATC1, governs FLT3<sup>ITD</sup>-driven hematopoietic stem cell transformation and a poor prognosis in AMLMaria Solovey, Ying Wang, Christian Michel, et al.
The Journal of Biological Chemistry|June 2, 2011
Disruption of a nuclear NFATc2 protein stabilization loop confers breast and pancreatic cancer growth suppression by zoledronic acidShiv K Singh, Sandra Baumgart, Garima Singh, et al.
Therapeutic Advances in Gastroenterology|February 18, 2022
Effectiveness of fourth-line dual immunotherapy in hepatocellular carcinoma with simultaneous steroid administration for immune-related hepatitisKristina Lowes, Johanna Reinecke, Marius Brunner, et al.
Studies in Health Technology and Informatics|September 5, 2024
A Concept for Mining Transitive Sequential Patterns from Pancreatic Cancer Patient JourneysJonas Hügel, Jan Janosch Schneider, Daniel Tran Ortega, et al.
European Journal of Immunology|December 4, 2015
NFATc1 releases BCL6-dependent repression of CCR2 agonist expression in peritoneal macrophages from Saccharomyces cerevisiae infected miceRhoda Busch, Krisna Murti, Jiming Liu, et al.
Case Reports in Gastroenterology|March 30, 2022
Cure Is Possible: Extensively Metastatic HER2-Positive Gastric Carcinoma with 5 years of Complete Remission after Therapy with the FLOT Regimen and TrastuzumabSebastian Schade, Ute Koenig, Ardian Mekolli, et al.
Nature Communications|June 18, 2016
A threshold level of NFATc1 activity facilitates thymocyte differentiation and opposes notch-driven leukaemia developmentStefan Klein-Hessling, Ronald Rudolf, Khalid Muhammad, et al.
Science Advances|July 4, 2025
<i>TP53</i> missense-specific transcriptional plasticity drives resistance against cell cycle inhibitors in pancreatic cancerLaura Urbach, Lena Wieland, Frederike Penz, et al.
Pageof 16